It will also distribute Mircera and Neorecormon – proven therapies for anemia in chronic kidney disease, including Mircera’s long-acting product with dosing once every 2–4 weeks.
The agreement would help expand access to therapies in chronic kidney disease (CKD), anemia management, and transplant care across India, the companies said in a joint communication.
Emcure will distribute Roche’s CellCept, an immunosuppressant and original Roche innovation supporting organ transplants worldwide since 1995, the companies said. It will also distribute Mircera and Neorecormon – proven therapies for anemia in chronic kidney disease, including Mircera’s long-acting product with dosing once every 2–4 weeks.
Emcure is a market leader in anemia management, and together with its subsidiaries, has a presence across nephrology and chronic kidney disease segments. Roche’s nephrology and transplant portfolio complements Emcure’s offerings, the note said.
Satish Mehta, Emcure Managing Director and Chief Executive said, the companies would together expand access to these critical therapies and support physicians in delivering care to patients across India. Rajji Mehdwan, Managing Director & CEO, Roche India & Neighbouring Markets, said, “Through Emcure’s strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients who can benefit from Roche’s long-standing innovations in transplant and CKD care.”
Published on March 2, 2026